Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Nathan

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
European Urology|May 27, 2011
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancerThomas Powles, Christian Blank, Simon Chowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2011
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancerIrfan Kayani, Norbert Avril, Jamshed Bomanji, et al.
Dermatology (Basel, Switzerland)|January 5, 2017
Unknown Primary Melanoma: Worldwide Survey on Clinical ManagementSimone Ribero, Riccardo Pampena, Veronique Bataille, et al.
Cancer Reports (Hoboken, N.J.)|January 8, 2026
Impact of a Reproductive Health Survivorship Care Plan on Fertility, Pregnancy Concerns, and Accessing Reproductive Healthcare Among Young Nulliparous Breast Cancer SurvivorsKsenya Shliakhtsitsava, Shaylyn S Stark, Tanushree Prasad, et al.
The Oncologist|June 24, 2025
Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanomaAmélie Ciernik, Laure Ciernik, Peter Bonczkowitz, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access programJohn W Walker, Celeste Lebbé, Giovanni Grignani, et al.
European Radiology|June 24, 2009
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trialDow-Mu Koh, Matthew Blackledge, David J Collins, et al.
Cancer Medicine|July 22, 2014
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCamillo Porta, Antonin Levy, Robert Hawkins, et al.
Journal of Cancer Survivorship : Research and Practice|December 13, 2024
The decision to disclose to your child they are a childhood cancer survivor: a qualitative study of barriers and facilitators using the theoretical domain frameworkJennifer Shuldiner, Bridgette Lord, Emma Rinaldo, et al.
The Journal of Investigative Dermatology|July 17, 2024
Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of ActionJessica C Hassel, Sarah Stanhope, Alexander Greenshields-Watson, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
European Urology|May 27, 2011
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancerThomas Powles, Christian Blank, Simon Chowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2011
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancerIrfan Kayani, Norbert Avril, Jamshed Bomanji, et al.
Dermatology (Basel, Switzerland)|January 5, 2017
Unknown Primary Melanoma: Worldwide Survey on Clinical ManagementSimone Ribero, Riccardo Pampena, Veronique Bataille, et al.
Cancer Reports (Hoboken, N.J.)|January 8, 2026
Impact of a Reproductive Health Survivorship Care Plan on Fertility, Pregnancy Concerns, and Accessing Reproductive Healthcare Among Young Nulliparous Breast Cancer SurvivorsKsenya Shliakhtsitsava, Shaylyn S Stark, Tanushree Prasad, et al.
The Oncologist|June 24, 2025
Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanomaAmélie Ciernik, Laure Ciernik, Peter Bonczkowitz, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access programJohn W Walker, Celeste Lebbé, Giovanni Grignani, et al.
European Radiology|June 24, 2009
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trialDow-Mu Koh, Matthew Blackledge, David J Collins, et al.
Cancer Medicine|July 22, 2014
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCamillo Porta, Antonin Levy, Robert Hawkins, et al.
Journal of Cancer Survivorship : Research and Practice|December 13, 2024
The decision to disclose to your child they are a childhood cancer survivor: a qualitative study of barriers and facilitators using the theoretical domain frameworkJennifer Shuldiner, Bridgette Lord, Emma Rinaldo, et al.
The Journal of Investigative Dermatology|July 17, 2024
Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of ActionJessica C Hassel, Sarah Stanhope, Alexander Greenshields-Watson, et al.
Pageof 13